Cologuard, another FDA-approved molecular diagnostic test for early CRC screening, included assays for 7 K-RAS point mutations, aberrant NDRG4 and BMP3 methylation with β-actin as a reference gene and a hemoglobin immunoassay. This evidence concerns the gene ACTB and colorectal carcinoma.